Objective To evaluate the efficacy and safety of gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene sensitive mutation. MethodsBased on the fixed time (April 2021 to April 2022), place (our hospital) and object (advanced NSCLC patients with EGFR gene sensitive mutation), 102 patients were selected and divided into two groups (two groups, random number table method, 51 patients in each group). Group A was treated with paclitaxel+carboplatin chemotherapy scheme, and Group B was treated with gefitinib targeted therapy based on this, with respect to the treatment effect (disease control rate) The tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), vascular endothelial growth factor (VEGF)] were compared, and the adverse reactions of the two groups were compared. Results The disease control rate of group B (68.63％) was significantly higher than that of group A (47.06％) (P＜0.05), while the incidence of adverse reactions was significantly lower than that of group A (9.80％ vs 25.49％) (P＜0.05). The levels of CEA, CA199 and VEGF in group B were lower than those in group A (P＜0.05).ConclusionTargeted therapy with gefitinib for patients with advanced NSCLC (EGFR gene sensitive mutation) is effective and safe, and can significantly reduce the level of tumor markers.
万方数据